49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 946 /  薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2021-000962-14-DE
(EUCTR)		02/07/202119/04/2021A drug trial to evaluate the safety and efficacy of daratumumab, an agent already approved for other diseases, in combination with standard background anti-rheumatic therapy in patients with moderate-to-severe systemic lupus erythematosusA Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus - DARALUP Systemic Lupus Erythematosus
MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Trade Name: Darzalex
Product Name: Daratumumab
Product Code: JNJ-54767414		Charité - Universitätsmedizin BerlinNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		10Phase 2Germany
2NCT04810754
(ClinicalTrials.gov)		June 30, 202111/3/2021An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus ErythematosusA Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: Daratumumab InjectionCharite University, Berlin, GermanyJanssen-Cilag G.m.b.H;Labor Berlin-Charité Vivantes G.m.b.H;Deutsches Rheuma-Forschungszentrum Berlin (DRFZ);Charité Clinical Trial Office (CTO)Not yet recruiting18 Years60 YearsAll10Phase 2NULL